


**FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) U.S. PATENT AND TRADEMARK OFFICE**

ATTY. DOCKET NO.
08-40155-US

SER. NO.
10/801,986

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(37 CFR 1.98(b))



APPLICANT

Kohn et al.

FILING DATE

March 16, 2004

GROUP

1614

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AA	5,556,754	9/17/1996	Singer et al.		
	AB	6,365,616	4/2/2002	Kohn et al.		

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BA					

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CA	Cybulsky et al. 1991. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251:788-791.
	CB	Schurmann et al. 1995. Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease. Gut 36:411-418.
	CC	Luscinskas et al. 1996. Endothelial-dependent mechanisms in chronic inflammatory leukocyte recruitment. Annu. Rev. Med. 47:413-421.
	CD	Soriano et al. 2000. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab. Invest. 80:1541-1551.
	CE	Panes et al. 1999. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 126:537-550.
	CF	Bevilacqua, M. P. 1993. Endothelial-leukocyte adhesion molecules. Annu. Rev. Immunol. 11:767-804.
	CG	Schindler et al. 1994. Three NF-kappa B binding sites in the human E-selectin gene required for maximal tumor necrosis factor alpha-induced expression. Mol Cell Biol 14:5820-5831.
	CH	Neish et al. 1992. Functional analysis of the human vascular cell adhesion molecule 1 promoter. J Exp Med 176:1583-1593.
EXAMINER		DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 08-40155-US	SER. NO. 10/801,986
	APPLICANT Kohn et al.	
	FILING DATE March 16, 2004	GROUP 1614

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CI	Neish et al. 1995. Sp1 is a component of the cytokine-inducible enhancer in the promoter of vascular cell adhesion molecule-1. J Biol Chem 270:28903-28909.
	CJ	Neish et al. 1995. Endothelial interferon regulatory factor 1 cooperates with NF-kappa B as a transcriptional activator of vascular cell adhesion molecule 1. Mol Cell Biol 15:2558-2569.
	CK	Iademarco et al. 1992. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). J Biol Chem 267:16323-16329.
	CL	Ledebur et al. 1995. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem 270:933-943.
	CM	Munoz et al. 1996. Transcriptional up-regulation of intracellular adhesion molecule-1 in human endothelial cells by the antioxidant pyrrolidine dithiocarbamate involves the activation of activating protein-1. J Immunol 157:3587-3597.
	CN	May et al. 1998. Signal transduction through NF-kappa B. Immunol Today 19:80-88.
	CO	Conner et al. 1997. Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 282:1615-1622.
	CP	Pierce et al. 1996. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol 156:3961-3969.
	CQ	Pierce et al. 1997. Novel inhibitors of cytokine-induced I kappa B phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 272:21096-21103.
	CR	Weber et al. 1995. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 91:1914-1917.
	CS	Umetani et al. 2000. A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA. Biochem Biophys Res Commun 272:370-374.
EXAMINER		DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 08-40155-US	SER. NO. 10/801,986
	APPLICANT Kohn et al.	
	FILING DATE March 16, 2004	GROUP 1614

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CT	Dagia et al. 2003. A proteasome inhibitor reduces concurrent, sequential and long term IL-1.β and TNF-α induced endothelial cell adhesion molecule expression and adhesion. Am. J. Phys. 285:C813-C822.
	CU	Cooper, D. S. 1984. Antithyroid drugs. N Engl J Med 311:1353-1362.
	CV	Elias et al. 1995. Effect of orally administered antithyroid thioureylenes on PCNA and P53 expression in psoriatic lesions. Int J Dermatol 34:280-283.
	CW	Chan et al. 1995. Periocular inflammation in mice with experimental systemic lupus erythematosus. A new experimental blepharitis and its modulation. J Immunol 154:4830-4835.
	CX	Davies et al. 1984. Influence of methimazole on murine thyroiditis. Evidence for immunosuppression in vivo. J Clin Invest 73:397-404.
	CY	Wang et al. 2003. Methimazole protects from experimental autoimmune uveitis by inhibiting antigen presenting cell function and reducing antigen priming. J Leukoc Biol 73:57-64.
	CZ	Saji et al. 1992. Major histocompatibility complex class I gene expression in rat thyroid cells is regulated by hormones, methimazole, and iodide as well as interferon. J Clin Endocrinol Metab 75:871-878.
	DA	Montani et al. 1998. Regulation of major histocompatibility class II gene expression in FRTL-5 thyrocytes: opposite effects of interferon and methimazole. Endocrinology 139:290-302.
	DB	Mozes et al. 1993. Resistance of MHC class I-deficient mice to experimental systemic lupus erythematosus. Science 261:91-93.
	DC	Wenisch et al. 1995. Circulating selecting, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism. J Clin Endocrinol Metab 80:2122-2126.
	DD	Oren et al. 1997. Anti-thyroid drugs decrease mucosal damage in a rat model of experimental colitis. Aliment Pharmacol Ther 11:341-345.
	DE	Suzuki et al. 1999. Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc Natl Acad Sci USA 96:2285-2290.
EXAMINER		DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

Kohn et al.

FILING DATE

March 16, 2004

GROUP

1614

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	DF	Gopalan et al. 1996. Cell adhesion under hydrodynamic flow conditions. In Current Protocols in Immunology. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, eds. J. Wiley, New York, p. 7.29.1-7.29.23.
	DG	Carlos et al. 1991. Human monocytes bind to two cytokine-induced adhesive ligands on cultured human endothelial cells: endothelial-leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1. Blood 77:2266-2271.
	DH	Zapolska-Downar et al. 2001. Selective inhibition by probucol of vascular cell adhesion molecule-1 (VCAM-1) expression in human vascular endothelial cells. Atherosclerosis 155:123-130.
	DI	Alon et al. 1994. Distinct cell surface ligands mediate T lymphocyte attachment and rolling on P- and E-selectin under physiological flow. J. Cell Biol. 127:1485-1495.
	DJ	Alon et al. 1995. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol 128:1243-1253.
	DK	Ochi et al. 2002. Hyperosmotic stimuli inhibit VCAM-1 expression in cultured endothelial cells via effects on interferon regulatory factor-1 expression and activity. Eur J Immunol 32:1821-1831.
	DL	Koo et al. 2003. Iron chelators inhibit VCAM-1 expression in human dermal microvascular endothelial cells. J Invest Dermatol 120:871-879.
	DM	Ahmad et al. 1998. Role of activating protein-1 in the regulation of the vascular cell adhesion molecule-1 gene expression by tumor necrosis factor-alpha. J Biol Chem 273:4616-4621.
	DN	Umetani et al. 2001. Function of GATA transcription factors in induction of endothelial vascular cell adhesion molecule-1 by tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol 21:917-922.
	DO	Kjellin et al. 1969. Tautomeric Cyclic Thiones. Part III. Preparation of N- and S-Methyl Derivatives of Some Azoline-2-thiones. Acta Chemica Scandinavica 23: 2879-2887.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.